BRPI0414026A - composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b - Google Patents

composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b

Info

Publication number
BRPI0414026A
BRPI0414026A BRPI0414026-5A BRPI0414026A BRPI0414026A BR PI0414026 A BRPI0414026 A BR PI0414026A BR PI0414026 A BRPI0414026 A BR PI0414026A BR PI0414026 A BRPI0414026 A BR PI0414026A
Authority
BR
Brazil
Prior art keywords
hbv
hepatitis
treatment
prevention
composition
Prior art date
Application number
BRPI0414026-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Karl Melber
Original Assignee
Rhein Biotech Proz & Prod Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech Proz & Prod Gmbh filed Critical Rhein Biotech Proz & Prod Gmbh
Publication of BRPI0414026A publication Critical patent/BRPI0414026A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0337Animal models for infectious diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0414026-5A 2003-08-29 2004-08-27 composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b BRPI0414026A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10339927A DE10339927A1 (de) 2003-08-29 2003-08-29 Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
PCT/EP2004/009590 WO2005023297A1 (de) 2003-08-29 2004-08-27 Zusammensetzung zur prophylaxe/therapie von hbv-infektionen und hbv-vermittelten erkrankungen

Publications (1)

Publication Number Publication Date
BRPI0414026A true BRPI0414026A (pt) 2006-10-24

Family

ID=34202216

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414026-5A BRPI0414026A (pt) 2003-08-29 2004-08-27 composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b

Country Status (11)

Country Link
US (2) US20060233832A1 (enExample)
EP (1) EP1660125B1 (enExample)
JP (1) JP4740133B2 (enExample)
KR (2) KR20120026138A (enExample)
CN (1) CN1874787B (enExample)
AU (1) AU2004269882B2 (enExample)
BR (1) BRPI0414026A (enExample)
CA (1) CA2535734A1 (enExample)
DE (1) DE10339927A1 (enExample)
ES (1) ES2541123T3 (enExample)
WO (1) WO2005023297A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
NZ598000A (en) * 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
AP2013007110A0 (en) * 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
JP6042871B2 (ja) 2011-04-21 2016-12-14 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. B型肝炎ウイルス(hbv)発現の調節
EP2629096A1 (en) * 2012-02-20 2013-08-21 Roche Diagniostics GmbH HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients
WO2014193122A1 (ko) * 2013-05-31 2014-12-04 (주)셀트리온 B형 간염 바이러스를 중화시킬 수 있는 결합 분자
CA2975660A1 (en) * 2015-03-16 2016-09-22 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Trispecific binding molecules for treating hbv infection and associated conditions
CN113058033B (zh) * 2019-12-16 2024-07-09 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
EP4471055A1 (en) * 2022-01-25 2024-12-04 Xiamen University Epitope peptide and antibody for treating hbv infection and related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
EP0389983A3 (en) * 1989-03-31 1991-01-16 Abbott Laboratories Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
PT97632A (pt) * 1990-05-11 1992-03-31 Scripps Clinic Res Processo de obtencao de polipeptidos relacionados com a proteina do antigenio de superficie do virus da hepatite b e de vacinas que os contem
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
US6133244A (en) * 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
ZA973367B (en) * 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
HK1048492A1 (zh) * 1999-12-03 2003-04-04 Innogenetics N.V. 新的hbv序列
JP2001294599A (ja) * 2000-04-12 2001-10-23 Sekisui Chem Co Ltd 組み換えb型肝炎ウィルス表面抗原
RU2286172C2 (ru) * 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
RU2233672C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии
RU2233673C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д

Also Published As

Publication number Publication date
CN1874787B (zh) 2012-09-19
EP1660125A1 (de) 2006-05-31
CN1874787A (zh) 2006-12-06
HK1100812A1 (en) 2007-09-28
CA2535734A1 (en) 2005-03-17
JP4740133B2 (ja) 2011-08-03
US20110263822A1 (en) 2011-10-27
WO2005023297A1 (de) 2005-03-17
JP2007504112A (ja) 2007-03-01
AU2004269882B2 (en) 2010-02-18
KR20120026138A (ko) 2012-03-16
ES2541123T3 (es) 2015-07-16
EP1660125B1 (de) 2015-05-06
KR20070019632A (ko) 2007-02-15
KR101250029B1 (ko) 2013-04-09
DE10339927A1 (de) 2005-03-24
AU2004269882A1 (en) 2005-03-17
US20060233832A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
BRPI0414026A (pt) composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b
Yi et al. Enterovirus 71 infection and vaccines
FI118118B (fi) Hepatiitti B -rokote
US9878035B2 (en) Hepatitis B vaccine
UA54364C2 (uk) Засіб для лікування гепатиту в, фармацевтична композиція та спосіб лікування
JP2013075920A (ja) インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのdsRNA
JP2022172244A5 (enExample)
Fernández et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac
CN104873969B (zh) 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗
RU2104700C1 (ru) Способ лечения гепатита в
CN113194945A (zh) 环吡酮的抑制hbv核心组装的用途
WO2010036230A1 (en) Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
WO2005016246A3 (en) Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
CN102050780B (zh) 喹啉衍生物,其药物组合物及其用途
TW201735945A (zh) 包括b型肝炎病毒之表面及核殼體抗原的藥學組成物
CN107693788B (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
EP1764369A1 (de) Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
Pandey et al. Essentials of COVID-19 and treatment approaches
CN1325048C (zh) 汉黄芩素在制备治疗或预防乙肝药物中的应用
Rymer et al. Interchangeability of 3 recombinant anti-HBV vaccines in primary schedule, irrespective of dose and HBsAg subtype: the first prospective, open-label, randomized study in healthy adult population
Suzuki Hiroshi Suzuki
CN106619591A (zh) 奥昔卡因在制备药物中的用途及药物组合物
T MDS et al. CATCH ME IF YOU CAN! SIMPLE STEPS SAVES LIVES-DENTAL PERSPECTIVE
RU2342952C1 (ru) Препарат, содержащий иммуноглобулин против боливийской геморрагической лихорадки из сыворотки крови лошадей, раствор для внутримышечного введения
MD3121F1 (en) Method of viral hepatitis B prophylaxis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.